Evidence map›Paper›PMID 28340444›Full record

ArticleJournal of affective disorders2017

Comparative effectiveness of dual-action versus single-action antidepressants for the treatment of depression in people living with HIV/AIDS.

Jon C Mills, Jeffrey S Harman, Robert L Cook, Nicole M Marlow, Christopher A Harle, R Paul Duncan, Angela M Bengtson, Brian W Pence

Abstract readComparative Study
In one paragraph

Article in Journal of affective disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Jon C MillsUniversity of North Carolina, Chapel Hill, Department of Epidemiology, United States. Electronic address: jon_mills@med.ufl.edu.
Jeffrey S HarmanFlorida State University, Department of Behavioral Sciences and Social Medicine, United States. Electronic address: jeffrey.harman@med.fsu.edu.
Robert L CookUniversity of Florida, Department of Epidemiology and Medicine, United States. Electronic address: cookrl@ufl.edu.
Nicole M MarlowUniversity of Florida, Department of Health Services Research, Management and Policy, United States. Electronic address: marlownm@phhp.ufl.edu.
Christopher A HarleIndiana University, Indianapolis, Department of Health Policy and Management, United States. Electronic address: charle@iu.edu.
R Paul DuncanUniversity of Florida, Department of Health Services Research, Management and Policy, United States. Electronic address: pduncan@ufl.edu.
Angela M BengtsonUniversity of North Carolina, Chapel Hill, Department of Epidemiology, United States. Electronic address: abengtso@live.unc.edu.
Brian W PenceUniversity of North Carolina, Chapel Hill, Department of Epidemiology, United States. Electronic address: bpence@unc.edu.
University of North Carolina at Chapel Hill · USFlorida Department of Health · USFlorida State University · USIndiana University – Purdue University Indianapolis · USUniversity of Florida · US

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Training in Sexually Transmitted Infections and HIVT32AI007001 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SENA-SOBERANO, ARLENE C. · 1985 to 2025
$10.9M
Southern HIV and Alcohol Research Consortium Administrative and Research Support CoreU24AA022002 · NIAAA · UNIVERSITY OF FLORIDA · PI COOK, ROBERT L · 2012 to 2022
$5.5M
NIAAA NIH HHS U24 AA022002NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI036219NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI094189NIAID NIH HHS R24 AI067039NIAID NIH HHS T32 AI007001NIDA NIH HHS U01 DA036935
6 · The paper itself

Abstract

backgroundDepression is the most common psychiatric comorbidity among people living with HIV/AIDS (PLWHA). Little is known about the comparative effectiveness between different types of antidepressants used to treat depression in this population. We compared the effectiveness of dual-action and single-action antidepressants in PLWHA for achieving remission from depression.

methodsWe used data from the Centers for AIDS Research Network of Integrated Clinic Systems to identify 1175 new user dual-action or single-action antidepressant treatment episodes occurring from 2005 to 2014 for PLWHA diagnosed with depression. The primary outcome was remission from depression defined as a Patient Health Questionnaire-9 (PHQ-9) score <5. Mean difference in PHQ-9 depressive symptom severity was a secondary outcome. The main approach was an intent-to-treat (ITT) evaluation complemented with a per protocol (PP) sensitivity analysis. Generalized linear models were fitted to estimate treatment effects.

resultsIn ITT analysis, 32% of the episodes ended in remission for both dual-action and single-action antidepressants. The odds ratio (OR) of remission was 1.02 (95%CI=0.63,1.67). In PP analysis, 40% of dual-action episodes ended in remission compared to 32% in single-action episodes. Dual-action episodes had 1.33 times the odds of remission (95%CI=0.55,3.21), however the result was not statistically significant. Non-significant differences were also observed for depressive symptom severity. LIMITATIONS: Missing data was common but was addressed with inverse probability weights.

conclusionsResults suggest that single-action and dual-action antidepressants are equally effective in PLWHA. Remission was uncommon highlighting the need to identify health service delivery strategies that aid HIV providers in achieving full remission of their patients' depression.

Indexed as

AdultAntidepressive Agents, Second-GenerationComparative Effectiveness ResearchDatabases, FactualDepressive DisorderFemaleHIV InfectionsHumansMaleRemission InductionSerotonin and Noradrenaline Reuptake InhibitorsAntidepressive Agents, Second-GenerationSerotonin and Noradrenaline Reuptake InhibitorsAntidepressantsComparative effectivenessDepressionHIV/AIDSInverse probability weightsNew user treatment episode

Identifiers

PMID28340444
PMCPMC5612416
OpenAlexW2596895959

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.